Development of AAV-CRISPR-Cas13 as novel antiviral strategies against medically important viral diseases

1.RNA viruses account for many human diseases and pandemic events but are often not targetable by traditional therapeutics modalities.

2. This study demonstrates the use of a new bioinformatics pipeline, establishes AAV-CRISPR-Cas13-gRNAs design principles that confer effective antiviral function, demonstrates in vivo prophylactic and therapeutic outcomes in lethal enterovirus-infected mouse models.
3. This study bolsters the feasibility of using AAVs as an efficient delivery vector for in vivo CRISPR-Cas13 antiviral treatment.